Dietary modifications often provide the first line of symptom management: Eat smaller, more frequent meals rather than large portions, which can overwhelm the already-slowed digestive system Reduce intake of gas-producing foods such as beans, lentils, cruciferous vegetables (broccoli, cauliflower, cabbage), onions, and carbonated drinks Limit high-fat foods , as these delay gastric emptying further and may compound the medication's effects Consider a low-FODMAP approach under dietitian supervision if symptoms are persistent, as fermentable carbohydrates can contribute to bloating Stay well-hydrated with still water throughout the day to support digestive function Avoid eating close to bedtime , allowing at least 3 hours between the last meal and lying down Lifestyle adjustments can also prove beneficial: Regular physical activity , particularly gentle walking after meals, can stimulate gastrointestinal motility and help move gas through the digestive tract Stress management techniques such as mindfulness or breathing exercises, as stress can exacerbate gastrointestinal symptoms Maintaining a symptom diary to identify specific food triggers or patterns Medication-related strategies should be discussed with your prescribing healthcare professional: Slower dose titration may reduce the intensity of gastrointestinal side effects Pausing escalation or stepping back to a previously tolerated dose if symptoms are troublesome Timing of administration considerations (note that while most GLP-1 RAs are not meal-timed, exenatide immediate-release [Byetta] is taken before meals) Review of concurrent medications that may contribute to bloating, such as certain antibiotics, opioids, or iron supplements Over-the-counter remedies such as simeticone (an anti-foaming agent) or peppermint oil capsules may provide symptomatic relief for some individuals, though evidence for their effectiveness varies
Medical References Information in this article is supported by the following medical sources: FDA Prescribing Information for Ozempic (Semaglutide) FDA Safety Guidance on GLP-1 Medications Ozempic Official Instructions for Use and Storage Healthline: Does Ozempic Need to Be Refrigerated
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
Semaglutide has a half-life of approximately seven days, which is why weekly dosing works
